(RTTNews) – Ipsen (IPSEY) said that by the 2020-2024 era, the company projects net TCAC sales between 2% and 5%. Ipsen plans to generate a cumulative firepower of 3 billion euros for the extension of the pipeline until 2024, selling assets.
Ipsen stated that the company aims to maximize the existing portfolio of specialty care products through advertising excellence and geographic expansion. The Group aims to maximize its flagship brands Somatuline, Decapeptyl and Dysport and capture the full perspective of its oncology Cabometyx and Onivyde. The company noted that a strategic review of Consumer Healthcare’s business is underway.
David Loew, CEO of Ipsen, said: “We will fulfill our commitment to oncology, rare diseases and neuroscience through accelerating our external innovation efforts and portfolio into clearly explained segments. Through prioritization and collaboration, we will improve the power to help investment. our pipeline. “